Q2 2018 13F Holders as of 6/30/2018
-
Type / Class
-
Debt / NOTE 3.250% 7/0
-
Number of holders
-
43
-
Total 13F principal, excl. options
-
359M
-
Principal change
-
-5.02M
-
Total reported value, excl. options
-
$315M
-
Value change
-
-$1.91M
-
Number of buys
-
17
-
Number of sells
-
-17
-
Price
-
$0.88
Significant Holders of INTERCEPT PHARMACEUTICALS IN - NOTE 3.250% 7/0 as of Q2 2018
49 filings reported holding 45845PAA6 - INTERCEPT PHARMACEUTICALS IN - NOTE 3.250% 7/0 as of Q2 2018.
INTERCEPT PHARMACEUTICALS IN - NOTE 3.250% 7/0 has 43 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of $359M of principal
.
Largest 10 bondholders include Allianz Asset Management GmbH ($43.4M of principal), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) ($36M of principal), OAKTREE CAPITAL MANAGEMENT LP ($34.5M of principal), ADVENT CAPITAL MANAGEMENT /DE/ ($25.1M of principal), AMERIPRISE FINANCIAL INC ($23.7M of principal), HIGHFIELDS CAPITAL MANAGEMENT LP ($21.5M of principal), MACKAY SHIELDS LLC ($17.6M of principal), STATE STREET CORP ($15.9M of principal), CITADEL ADVISORS LLC ($15.5M of principal), and Graham Capital Management, L.P. ($13.6M of principal).
This table shows the top 43 institutional bondholders of the company debt. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.